GlassScriptPhysician profile
Cameron Fisher
NPI 1073187936
$12,114.71
in general payments reported to CMS, 2019-2025
62 companies · $2,786 in 2025
The $2,786 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $890 · 2023: $4,602 · 2024: $3,837 · 2025: $2,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,465.35 |
| Education | $759.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $768.71 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $759.10 | 2022-2025 | Enhertu, Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $724.19 | 2022-2025 | |
| Janssen Biotech, INC. | $698.44 | 2022-2025 | Carvykti, Erleada, Tecvayli |
| Pfizer INC. | $624.14 | 2022-2025 | |
| Incyte Corporation | $499.22 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Daiichi Sankyo INC. | $476.03 | 2022-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $403.70 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Celgene Corporation | $376.38 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Exelixis INC. | $371.83 | 2022-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $365.51 | 2022-2025 | Ninlaro, Iclusig, Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $347.37 | 2022-2025 | |
| Amgen INC. | $336.80 | 2022-2023 | Lumakras, Nplate, Vectibix |
| Genzyme Corporation | $326.36 | 2022-2025 | |
| Array Biopharma INC | $320.47 | 2022-2024 | Braftovi, Lorbrena, Mektovi |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $283.35 | 2023-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $246.21 | 2023-2025 | Xtandi |
| Gilead Sciences, INC. | $233.52 | 2022-2025 | Trodelvy |
| Sumitomo Pharma America, INC. | $228.03 | 2023-2024 | Orgovyx |
| Sobi, INC | $218.17 | 2023-2025 | |
| Seagen INC. | $216.57 | 2022-2025 | Padcev |
| Lilly USA, LLC | $213.82 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $200.71 | 2022-2024 | Venclexta, Tecentriq, Erivedge |
| Abbvie INC. | $196.27 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $195.34 | 2023-2024 | Onivyde, Somatuline Depot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.18 | 2022-2024 | Gilotrif |
| Adaptive Biotechnologies Corporation | $176.24 | 2024-2025 | Clonoseq |
| Deciphera Pharmaceuticals INC. | $175.50 | 2022-2025 | Qinlock, Romvimza, Tgct |
| Beigene USA, INC. | $151.04 | 2023-2024 | Brukinsa |
| Janssen Scientific Affairs, LLC | $144.81 | 2023 | Erleada |
| Pharmaessentia USA Corporation | $143.55 | 2023-2024 | Besremi |
| Karyopharm Therapeutics INC. | $135.10 | 2023-2024 | Xpovio |
| Emd Serono, INC. | $118.49 | 2022-2024 | Bavencio |
| Jazz Pharmaceuticals INC. | $111.60 | 2023-2024 | |
| Tersera Therapeutics LLC | $99.77 | 2023-2024 | Zoladex |
| Servier Pharmaceuticals LLC | $88.26 | 2025 | |
| Eisai INC. | $76.15 | 2023-2025 | |
| Taiho Oncology, INC. | $73.76 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $67.77 | 2023 | Givlaari |
| Aveo Pharmaceuticals, INC. | $60.05 | 2022-2023 | Fotivda |
| Mirati Therapeutics, INC. | $59.13 | 2023 | Krazati |
| Immunogen, INC. | $51.07 | 2023-2024 | Elahere, Elahere |
| Boston Scientific Corporation | $47.14 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Blueprint Medicines Corporation | $46.99 | 2023 | Ayvakit |
| Adc Therapeutics America, INC. | $44.66 | 2024 | |
| Myriad Genetic Laboratories, INC. | $38.65 | 2024 | Myrisk |
| Kyowa Kirin, INC. | $37.15 | 2023 | Poteligeo |
| Stemline Therapeutics INC. | $36.25 | 2023 | Orserdu |
| Genmab U.S., INC. | $29.09 | 2025 | |
| Alexion Pharmaceuticals, INC. | $29.02 | 2025 | Ultomiris |
| Springworks Therapeutics, INC. | $27.68 | 2025 | Ogsiveo |
| Novocure INC. | $27.50 | 2024 | Optune |
| Sun Pharmaceutical Industries INC. | $23.15 | 2023 | Yonsa |
| Beone Medicines USA, INC. | $22.93 | 2025 | Brukinsa |
| Catalyst Pharmaceuticals, INC. | $22.54 | 2023 | Firdapse |
| Recordati_rare_diseases_inc. | $21.27 | 2025 | Enjaymo |
| Rigel Pharmaceuticals, INC. | $19.76 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Aadi Bioscience, INC. | $18.38 | 2025 | Fyarro |
| Agios Pharmaceuticals, INC. | $18.06 | 2023 | |
| Epizyme, INC. | $17.99 | 2022 | |
| Tolmar, INC. | $16.13 | 2023 | |
| Syndax Pharmaceuticals, INC. | $15.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.